The protective effects of ursodeoxycholic acid and the selective cyclooxygenase-2 inhibitor celecoxib on liver damage in an experimental cholestasis model

Basit Öğe Kaydı
dc.authorid0000-0001-8028-1671
dc.contributor.authorKüçük, Adem
dc.contributor.authorÖztürk, Hülya Çuvalcı
dc.date.accessioned2021-06-23T18:27:14Z
dc.date.available2021-06-23T18:27:14Z
dc.date.issued2019
dc.departmentBAİBÜ, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümüen_US
dc.description.abstractAim: Cholestasis leads to liver cell death, fibrosis, cirrhosis, and eventually liver failure. Ursodeoxycholic acid (UDCA) is the only Food and Drug Administration-approved treatment for cholestatic disorders. Hepatic cyclooxygenase-2 (COX-2) expression increases in various chronic liver diseases caused either by viruses or toxins. The present study was conducted to investigate the effects of UDCA and the selective COX-2 inhibitor celecoxib on inflammation and fibrogenesis in a rat model of cholestasis induced by bile duct ligation (BDL). Methods: Fifty Sprague–Dawley rats that underwent common BDL for 21 days were assigned to one of five treatment groups (sham-operation, BDL, daily UDCA treatment following BDL, daily celecoxib treatment following BDL, and daily celecoxib and UDCA combination treatment following BDL). Serum and liver samples were collected after 21 days. Fibrosis, ductular proliferation, and portal inflammation were scored in liver samples. Liver function tests were evaluated. Results: In comparison with the control group, the BDL group showed hepatic damage as evidenced by elevation in serum biochemical and histological changes such as ductular reaction, fibrosis, and inflammation. These pathophysiological changes were attenuated by chronic UDCA and selective COX-2 inhibitor celecoxib supplementation. Conlusion: Our findings indicate that the addition of Celecoxib to UDCA reduces liver inflammation and fibrosis and might be an effective supplemental therapy with UDCA for cholestatic diseases. The beneficial effects of chronic UDCA and Celecoxib supplementation may be associated with their potential cytoprotective, anti-oxidative and anti-inflammatory effects.en_US
dc.identifier.doi10.30714/j-ebr.2019250350
dc.identifier.endpage61en_US
dc.identifier.issn2618-6454
dc.identifier.issn2618-6454
dc.identifier.issue2en_US
dc.identifier.startpage50en_US
dc.identifier.trdizinid370403en_US
dc.identifier.urihttps://doi.org/10.30714/j-ebr.2019250350
dc.identifier.urihttps://app.trdizin.gov.tr/makale/TXpjd05EQXpNdz09
dc.identifier.urihttps://hdl.handle.net/20.500.12491/1626
dc.identifier.volume2en_US
dc.indekslendigikaynakTR-Dizinen_US
dc.institutionauthorÖztürk, Hülya Çuvalcı
dc.language.isoenen_US
dc.relation.ispartofExperimental Biomedical Researchen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCholestasis
dc.subjectHepatic Fibrosis
dc.subjectUrsodeoxycholic Acid
dc.subjectCelecoxib
dc.subjectCyclooxygenase-2
dc.titleThe protective effects of ursodeoxycholic acid and the selective cyclooxygenase-2 inhibitor celecoxib on liver damage in an experimental cholestasis modelen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
adem-kucuk.pdf
Boyut:
3.04 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam metin/ Full text
İndir

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu
Cerrahi Tıp Bilimleri Bölümü Koleksiyonu